Postpartum Mh Htn denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for postpartum mh htn are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Postpartum Mental Health and Hypertension Treatment as Not FDA-Approved

Humana may issue a "not FDA-approved" denial when a medication is being used for an indication, patient population, or route of administration not explicitly listed in the FDA-approved labeling — commonly called "off-label" use. In postpartum mental health and hypertension care, off-label prescribing is clinically common and is recognized as legitimate medical practice. The FDA itself does not prohibit off-label prescribing; it governs manufacturer promotion, not physician practice.

## Why This Denial Is Highly Appealable

Insurers including Humana are generally required — under applicable state and federal law — to cover off-label uses of FDA-approved drugs when the use is supported by recognized medical compendia or substantial clinical evidence. Most state insurance codes and CMS guidelines for Medicare/Medicaid plans reference specific compendia (such as the DRUGDEX/Micromedex system) as the standard for evaluating off-label coverage. If your medication's off-label use is listed in a recognized compendium with a favorable evidence rating, Humana's denial is likely contrary to its own coverage obligations.

## Federal Appeal Framework

• Internal appeal: File under ERISA §503 (employer plan) or applicable state law, citing the specific compendium entry or professional society guideline supporting this use in postpartum patients. Include the timeline noted on your denial letter.
• External review (ACA §2719): Available within approximately four months of a final internal denial. An independent IRO will assess whether the off-label use meets recognized clinical standards — this is exactly the kind of question IROs are well-suited to evaluate.
• Expedited review: Postpartum conditions can escalate rapidly; request the expedited track (typically 72 hours) at both internal and external stages.

## Documentation to Gather

1. FDA-approved prescribing label: Obtain the current label for the medication. Even if the exact postpartum indication is absent, the label's pharmacology, safety, and mechanism sections may support the use. 2. Compendia reference: Ask your pharmacist or prescriber to print the relevant DRUGDEX, Clinical Pharmacology, or other recognized compendium entry showing this use is supported. 3. Professional society guidelines: A citation to guidance from ACOG, the American Psychiatric Association, or another applicable society endorsing this use in postpartum patients strengthens your appeal substantially. 4. Prescriber medical-necessity letter: Explaining the clinical basis for this off-label use in your specific case, the evidence the prescriber is relying on, and why on-label alternatives are inadequate. 5. Diagnosis and treatment history: Confirming the postpartum diagnosis, severity, and any prior treatments tried.

## Criteria-Mapping Structure

Humana's off-label coverage policy will specify which compendia or evidence standards it recognizes. Obtain that policy and map:

| Humana Off-Label Coverage Criterion | Your Evidence | |---|---| | Use listed in recognized compendium | [Compendium name, rating, printout attached] | | Supported by professional society guideline | [Organization, guideline name/version, page reference] | | FDA-approved drug (even if off-label use) | [Confirmed: drug is FDA-approved for [on-label indication]] | | Prescriber clinical rationale | [Letter from Dr. XX, dated XX] |

A denial on "not FDA-approved" grounds where the drug itself is FDA-approved (just used off-label) is a common insurer error — flag this distinction explicitly in your appeal letter.